# Mise au point des patients cardiaques pour chirurgie non-cardiaque

- Cours EIUA
- 11 fév 2023


- D. Schmartz


Le Monde

SCIENCES ET MEDECINE

# Le luxe des examens de routine

**La plupart des examens pré-opératoires systématiques ne sont pas justifiés, et leur coût grève le budget de la Sécurité sociale.**

LA grande majorité des examens pratiqués de manière systématique avant une intervention chirurgicale ne présentent aucun intérêt médical et devraient être abandonnés. Telle est la spectaculaire conclusion d'une étude originale menée à l'hôpital Rothschild (Assistance publique de Paris). Cette conclusion est renforcée par l'initiative d'un groupe de spécialistes en radiologie qui veut faire savoir que les examens radiologiques du thorax pratiqués de manière systématique sont la plupart du temps totalement injustifiés (*le Monde* du 30 avril). Deux informations qui mettent en lumière le caractère souvent irrationnel autant qu'inefficace de la prescription des examens complémentaires dans les établissements hospitaliers.

Le fait est totalement inhabi- radio-diagnostic), et que ceux-ci coûtent chaque année environ 600 millions de francs. « *A l'heure où le médecin dispose de moyens de plus en plus sophistiqués dans un contexte de limitation de la croissance des ressources affectées aux dépenses de santé, il importe de rationaliser la pratique, même au niveau des examens les plus simples* », expliquent le docteur Guy Frija (hôpital Raymond-Poincaré, Garches) et MM. Christian Lefaure et François Fagnani (unité 240, INSERM).

Replacées dans un contexte international, les conclusions des spécialistes français ne sont pas véritablement surprenantes. Depuis le début des années 80, plusieurs pays, puis l'Organisation mondiale de la santé, ont en effet cherché à évaluer puis à rationaliser la pratique des examens radiologiques systématiques. En 1984, aux Etats-Unis, la Food and Drug Administration est même allée jusqu'à indiquer, dans une brochure destinée au grand public, l'inutilité d'une pratique systématique et le risque potentiel des irradiations répétées. « *En France,* explique le docteur Frija, *le ministère de la santé va diffuser une brochure intitulée* le Praticien et la tuberculose *dans laquelle il est expressément dit que le dépistage radiographique doit être réservé à certaines catégories de sujets particulièrement exposés aux risques de tuberculose : personnes âgées, immigrés, immuno-déprimés, etc. Cet examen ne devra être effectué que sur prescription médicale.* »

Actuellement, la radiographie de dépistage de la tuberculose, pratiquée de manière routinière par les services de l'Action sanitaire et sociale et par la médecine du travail, représente près de neuf millions d'examens annuels. Une surveillance particulièrement inadaptée et mal ciblée, puisque cent mille de ces examens ne permettent de dépister que quinze cas de tuberculose, soit un coût moyen par dépistage de 200 000 à 300 000 francs.

## Des résultats éloquents

Mais le réquisitoire sévère autant que justifié contre la radiographie thoracique de routine ne doit pas cacher un autre gaspillage, plus considérable encore, celui des examens paracliniques pré-opératoires, c'est-à-dire l'ensemble des examens autres que l'examen clinique du malade. Ces examens sont demandés de manière quasi systématique avant chaque intervention chirurgicale. Il s'agit en règle générale d'un électrocardiogramme et d'une batterie d'analyses biologiques portant sur le sang (groupe sanguin, taux d'hémoglobine) sur les facteurs de la coagulation sanguine, la fonction rénale, etc., auxquels il faut ajouter, là encore, une radiographie du thorax.

La première étude française visant à évaluer l'utilité d'un tel bilan pré-opératoire a été menée à l'hôpital Rothschild de Paris à l'initiative du docteur Christian Bléry. Ses résultats ont été publiés il y a quelques mois dans l'hebdomadaire médical *The Lancet* (2). Ils ont d'autre part fait très récemment l'objet d'une confirmation dans le cadre d'une étude nationale groupant des établissements publics et privés. Les résultats sont en cours de dépouillement. Ils pourraient faire u rieurement l'objet de recomm dations officielles émanant autorités françaises l'anesthésie-réanimation.

« *Au début des années* explique le docteur Bléry, *seu groupe à San-Francisco et q ques équipes scandinaves s'i ressaient à ce sujet. Les man d'anesthésie et de chirurgie co nuaient alors à préconiser bilans systématiques, s réflexion.* »

JEAN-YVES NAU

*(Lire la suite page 29.)*

(1) *Le Concours médical,* nu du 2 mai 1987.

(2) *The Lancet,* numéro du 18 vier 1986. Ce travail a également l'objet d'une publication dans *Annales françaises d'anesthé réanimation* (6-64-70-1987).

## LES MONGOLIENS DE TCHERNOBYL

# 2007 American College of Cardiology/American Heart Association (ACC/AHA) Guidelines on Perioperative Cardiac Evaluation Are Usually Incorrectly Applied by Anesthesiology Residents Evaluating Simulated Patients

RESULTS: The 548 resident participants, representing 12% of anesthesiology trainees in the United States, included 48 PGY-1s (preliminary year before anesthesia training), 166 Clinical Anesthesia Year 1 (CA-1) residents, 161 CA-2s, and 173 CA-3s. For patients with an active cardiac condition, the upper 95% confidence bound for the percent of residents who recommended evaluations consistent with the guidelines was 78%. However, for the remaining 5 scenarios, the upper 95% confidence bound for the percent of residents with an appropriate recommendation was 46%.

CONCLUSIONS: The results show that fewer than half of anesthesiology residents nationwide correctly demonstrate the approach considered the standard of care for preoperative cardiac evaluation. Further study is necessary to elucidate the correct intervention(s), such as use of decision support tools, increased clarity of guidelines for routine use, adjustment in educational programs, and/or greater familiarity of responsible faculty with the material.

M. Vigoda et al, AnesthAnalg 2011;112:940–9

# Evènements cardio-vasculaires – NCS  H

- N = 46.539, > 16 ans
  - Suivi à 60 jours
  - 4% (1855) décès avant la sortie
    - Dont 73% jamais admis en USI
  - 8% USI, durée moyenne 1,5 j




Mortality after surgery in Europe: a 7 day cohort study, The Lancet 2012 Sep 22;380(9847):1059-65.

EJA

*Eur J Anaesthesiol* 2018; **35**:407–465

GUIDELINES

## Pre-operative evaluation of adults undergoing elective noncardiac surgery

*Updated guideline from the European Society of Anaesthesiology*

Stefan De Hert*, Sven Staender, Gerhard Fritsch, Jochen Hinkelbein, Arash Afshari, Gabriella Bettelli, Matthias Bock, Michelle S. Chew, Mark Coburn, Edoardo De Robertis, Hendrik Drinhaus, Aarne Feldheiser, Götz Geldner, Daniel Lahner, Andrius Macas, Christopher Neuhaus, Simon Rauch, Maria Angeles Santos-Ampuero, Maurizio Solca, Nima Tanha, Vilma Traskaite, Gernot Wagner and Frank Wappler



SFAR Société Française d'Anesthésie et de Réanimation

Société Française de Cardiologie

**Recommandations formalisées d'experts SFAR/SFC**

## Prise en charge du coronarien qui doit être opéré en chirurgie non cardiaque

*Société française d'anesthésie et de réanimation*
*Société française de cardiologie*

ELSEVIER CrossMark

Canadian Journal of Cardiology 33 (2017) 17–32

**Society Guidelines**

## Canadian Cardiovascular Society Guidelines on Perioperative Cardiac Risk Assessment and Management for Patients Who Undergo Noncardiac Surgery

Emmanuelle Duceppe, MD,[a,b,c] Joel Parlow, MD, MSc (Co-chair),[d] Paul MacDonald, MD,[e] Kristin Lyons, MDCM,[f] Michael McMullen, MD,[d] Sadeesh Srinathan, MD, MSc,[g] Michelle Graham, MD,[h] Vikas Tandon, MD,[i] Kim Styles, MD,[j] Amal Bessissow, MD, MSc,[k] Daniel I. Sessler, MD,[l] Gregory Bryson, MD, MSc,[m,n] and P.J. Devereaux, MD, PhD (Co-chair)[b,c,i]

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
VOL. 64, NO. 22, 2014

PUBLISHED BY ELSEVIER INC.
ISSN 0735-1097/$36.00
http://dx.doi.org/10.1016/j.jacc.2014.07.944

CLINICAL PRACTICE GUIDELINE

## 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery

CrossMark

A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

ESC European Society of Cardiology

European Heart Journal (2022) **43**, 3826–3924
https://doi.org/10.1093/eurheartj/ehac270

ESC GUIDELINES

## 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery

**Developed by the task force for cardiovascular assessment and management of patients undergoing non-cardiac surgery of the European Society of Cardiology (ESC)**

**Endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC)**

EJA

*Eur J Anaesthesiol* 2014; **31**:517–573

GUIDELINES

## 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management

*The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA)*

# Recommandation

| Risque cardiaque péri opératoire | |
|---|---|
| Risque lié au patient | Risque lié à la chirurgie |
| Antécédents du patient : Score de Lee | |
| Capacité à faire un effort<br>(réserve fonctionnelle) | |

# Recommandation



# Capacité fonctionnelle

V

Estimé sur questionnaire : **Duke Activity Status Index (DASI)**
Total 58,2

Score < 34 → majore le risque

(Exemple: Ne monte pas les escaliers : 13,45 → 3,8METs)

X

La limite des 4 METs basé sur l'anamnèse (Guidelines 2014)

The Duke Activity Status Index (DASI) is a self-administered questionnaire that measures a patient's functional capacity. It can be used to get a rough estimate of a patient's peak oxygen uptake.

**Instructions: Please circle yes or no to the following questions.**

| Item | Activity | Yes | No |
|---|---|---|---|
| 1 | Can you take care of yourself (eating dressing bathing or using the toilet)? | 2.75 | 0 |
| 2 | Can you walk indoors such as around your house? | 1.75 | 0 |
| 3 | Can you walk a block or two on level ground? | 2.75 | 0 |
| 4 | Can you climb a flight of stairs or walk up a hill? | 5.50 | 0 |
| 5 | Can you run a short distance? | 8.00 | 0 |
| 6 | Can you do light work around the house like dusting or washing dishes? | 2.70 | 0 |
| 7 | Can you do moderate work around the house like vacuuming, sweeping floors, or carrying in groceries? | 3.50 | 0 |
| 8 | Can you do heavy work around the house like scrubbing floors or lifting and moving heavy furniture? | 8.00 | 0 |
| 9 | Can you do yard work like raking leaves, weeding, or pushing a power mower? | 4.50 | 0 |
| 10 | Can you have sexual relations? | 5.25 | 0 |
| 11 | Can you participate in moderate recreational activities like golf, bowling, dancing, doubles tennis, or throwing a baseball or football? | 6.00 | 0 |
| 12 | Can you participate in strenuous sports like swimming, singles tennis, football, basketball, or skiing? | 7.50 | 0 |
| | **Total Score =** | | |
| | **Estimate peak O2 = .43 * (DASI) + 9.6 =** | | |
| | **METS = ( / 3.5 )** | | |

**Patient** (signature): _____ Date: _____ Time: _____

# 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery

## Official ESC Guidelines slide set

ESC
European Society of Cardiology

# 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery

The material was adapted from the *'2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC)'* (*European Heart Journal*; 2022 - doi: 10.1093/eurheartj/ehac270).

# 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery

## Authors/Task Force Members:

**Sigrun Halvorsen(Chairperson) (Norway), Julinda Mehilli (Chairperson) (Germany),** Salvatore Cassese (Task Force Coordinator) (Germany), Trygve S. Hall (Task Force Coordinator) (Norway), Magdy Abdelhamid (Egypt), Emanuele Barbato (Italy/Belgium), Stefan De Hert[1] (Belgium), Ingrid de Laval (Sweden), Tobias Geisler (Germany), Lynne Hinterbuchner (Austria), Borja Ibanez (Spain), Radosław Lenarczyk (Poland), Ulrich R. Mansmann (Germany), Paul McGreavy (United Kingdom), Christian Mueller (Switzerland), Claudio Muneretto (Italy), Alexander Niessner (Austria), Tatjana S. Potpara (Serbia), Arsen Ristić (Serbia), L. Elif Sade (United States of America/Turkey), Henrik Schirmer (Norway), Stefanie Schüpke (Germany), Henrik Sillesen (Denmark), Helge Skulstad (Norway), Lucia Torracca (Italy), Oktay Tutarel (Germany), Peter Van Der Meer (Netherlands), Wojtek Wojakowski (Poland), Kai Zacharowski[1] (Germany).

[1] Representing the European Society of Anaesthesiology and Intensive Care (ESAIC)

# 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery

## ESC subspecialty communities having participated in the development of this document:

**Associations**: Association for Acute CardioVascular Care (ACVC), Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of Cardiovascular Imaging (EACVI), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).
**Councils**: Council of Cardio-Oncology, Council on Valvular Heart Disease.
**Working Groups**: Adult Congenital Heart Disease, Aorta and Peripheral Vascular Diseases, Cardiovascular Pharmacotherapy, Cardiovascular Surgery, Thrombosis.
**ESC Patient Forum**

# ESC Classes of recommendations








2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# ESC Levels of evidence

| | |
|---|---|
| Level of evidence A | Data derived from multiple randomized clinical trials or meta-analyses. |
| Level of evidence B | Data derived from a single randomized clinical trial or large non-randomized studies. |
| Level of evidence C | Consensus of opinion of the experts and/or small studies, retrospective studies, registries. |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (1)

| Recommendations | Class |
|---|---|
| ***Clinical risk evaluation — Patients scheduled for non-cardiac surgery*** | |
| In all patients scheduled for NCS, an accurate history, and clinical examination are recommended. | I |
| It is recommended to perform a pre-operative risk assessment, ideally at the same time as the NCS is proposed. | I |
| If time allows, it is recommended to optimize guideline-recommended treatment of CVD and CV risk factors before NCS. | I |
| Endovascular or video-assisted procedures should be considered for patients with high CV risk undergoing vascular or pulmonary surgery. | IIa |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (2)

| Recommendations | Class |
|---|---|
| ***Clinical risk evaluation — Patients <65 years without signs, symptoms, or history of CVD*** | |
| In patients with a family history of genetic cardiomyopathy, it is recommended to perform an ECG and TTE before NCS regardless of age and symptoms. | I |
| In patients 45–65 years of age without signs, symptoms, or history of CVD, ECG, and biomarkers should be considered before high-risk NCS. | IIa |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (3)

| Recommendations | Class |
|---|---|
| ***Clinical risk evaluation — Pre-operative assessment in patients with a newly detected murmur, chest pain, dyspnoea, or peripheral oedema*** | |
| In patients with a newly detected murmur *and* symptoms or signs of CVD, TTE is recommended before NCS. | I |
| In patients with a newly detected murmur suggesting clinically significant pathology, TTE is recommended before high-risk NCS. | I |
| In patients with a newly detected murmur, but without other signs or symptoms of CVD, TTE should be considered before moderate and high-risk NCS. | IIa |
| If a patient scheduled for elective NCS has chest pain or other symptoms suggestive of undetected CAD, further diagnostic work-up before NCS is recommended. | I |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (4)

| Recommendations | Class |
|---|---|
| ***Clinical risk evaluation — Pre-operative assessment in patients with a newly detected murmur, chest pain, dyspnoea, or peripheral oedema (continued)*** | |
| If a patient in need of acute NCS also has chest pain or other symptoms suggestive of undetected CAD, a multidisciplinary assessment approach is recommended to choose the treatment with lowest total risk for the patient. | I |
| In patients with dyspnoea and/or peripheral oedema, an ECG and an NT-proBNP/BNP test is indicated before NCS, unless there is a certain non-cardiac explanation. | I |
| In patients with dyspnoea and/or peripheral oedema and elevated NT-proBNP/BNP, TTE is recommended before NCS. | I |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (5)

| Recommendations | Class |
|---|---|
| ***Clinical risk evaluation — Patient information*** | |
| It is recommended to give patients individualized instructions for pre-operative and post-operative changes in medication, in verbal and written formats with clear and concise directions. | I |
| It should be considered to set up a structured information list (e.g. a check list to help with common issues) for patients with CVD or at high risk of CV complications scheduled for NCS. | IIa |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (6)

| Recommendations | Class |
|---|---|
| ***Preoperative assessment tools — Frailty and physical capacity*** | |
| In patients ≥70 years old, being scheduled to undergo intermediate- or high-risk NCS, frailty screening should be considered using a validated screening tool. | IIa |
| Adjusting risk assessments according to self-reported ability to climb two flights of stairs should be considered in patients referred for intermediate- or high-risk NCS. | IIa |
| ***Preoperative assessment tools — Transthoracic echocardiography*** | |
| TTE is recommended in patients with poor functional capacity and/or high NT-proBNP/BNP, or, if murmurs are detected before high-risk NCS, in order to undertake risk-reduction strategies. | I |
| TTE should be considered in patients with suspected new CVD or unexplained signs or symptoms before high-risk NCS. | IIa |
| TTE may be considered in patients with poor functional capacity, abnormal ECG, high NT-proBNP/BNP, or ≥1 clinical risk factor before intermediate-risk NCS. | IIb |
| To avoid delaying surgery, a FOCUS exam performed by trained specialists may be considered as an alternative to TTE for pre-operative triage. | IIb |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (7)

| Recommendations | Class |
|---|---|
| ***Preoperative assessment tools — Stress imaging*** | |
| Stress imaging should be considered before high-risk NCS in asymptomatic patients with poor functional capacity, and prior PCI or CABG. | **IIa** |
| ***Preoperative assessment tools — Coronary angiography*** | |
| CCTA should be considered to rule out CAD in patients with suspected CCS or biomarker-negative NSTE-ACS in case of low-to-intermediate clinical likelihood of CAD, or in patients not suitable for non-invasive functional testing undergoing non-urgent, intermediate-, and high-risk NCS. | **IIa** |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (8)

| Recommendations | Class |
|---|---|
| ***General risk-reduction strategies — Cardiovascular risk factors and lifestyle interventions*** | |
| Smoking cessation more than 4 weeks before NCS is recommended to reduce post-operative complications and mortality. | I |
| Control of CV risk factors, including blood pressure, dyslipidaemia, and diabetes, is recommended before NCS. | I |
| ***General risk-reduction strategies — Pharmacological treatment*** | |
| For patients on diuretics to treat hypertension, transient discontinuation of diuretics on day of NCS should be considered. | IIa |
| It should be considered to interrupt SGLT-2 inhibitor therapy for at least 3 days before intermediate- and high-risk NCS. | IIa |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (9)

| Recommendations | Class |
|---|---|
| ***General risk-reduction strategies — Antiplatelets*** | |
| For patients undergoing high bleeding risk surgery (e.g. intracranial, spinal neurosurgery, or vitroretinal eye surgery), it is recommended to interrupt aspirin for at least 7 days pre-operatively. | I |
| In high-risk patients with a recent PCI (e.g. STEMI patients or high-risk NSTE-ACS patients), a DAPT duration of at least 3 months should be considered before time-sensitive NCS. | IIa |
| ***General risk-reduction strategies — Anticoagulants*** | |
| When an urgent surgical intervention is required, it is recommended that NOAC therapy is immediately interrupted. | I |
| In non-minor bleeding risk procedures in patients using a NOAC, it is recommended to use an interruption regimen based on the NOAC compound, renal function, and bleeding risk. | I |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (10)

| Recommendations | Class |
|---|---|
| ***General risk-reduction strategies — Anticoagulants (continued)*** | |
| In minor bleeding risk surgery and other procedures where bleeding can be easily controlled, it is recommended to perform surgery without interruption of OAC therapy. | I |
| In patients using NOACs, it is recommended that minor bleeding risk procedures are performed at trough levels (typically 12–24 h after last intake). | I |
| LMWH is recommended, as an alternative to UFH, for bridging in patients with MHVs and high surgical risk. | I |
| For patients with mechanical prosthetic heart valves undergoing NCS, bridging with UFH or LMWH should be considered if OAC interruption is needed and patients have: (i) mechanical AVR and any thromboembolic risk factor; (ii) old-generation mechanical AVR; or (iii) mechanical mitral or tricuspidal valve replacement. | IIa |
| Idarucizumab should be considered in patients on dabigatran and requiring urgent surgical intervention with intermediate to high bleeding risk. | IIa |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (11)

| Recommendations | Class |
|---|---|
| ***General risk-reduction strategies — Anticoagulants (continued)*** | |
| For interventions with a very high risk of bleeding, such as spinal or epidural anaesthesia, interruption of NOACs for up to five half-lives and re-initiation after 24 h should be considered. | **IIa** |
| When specific reversal agents are not available, PCC or activated PCC should be considered for reversing NOAC effects. | **IIa** |
| If an urgent surgical intervention is required, specific coagulation tests and assessment of NOAC plasma levels should be considered to interpret routine coagulation tests and waning of anticoagulant effect. | **IIa** |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (12)

| Recommendations | Class |
|---|---|
| ***General risk-reduction strategies — Anticoagulants (continued)*** | |
| If bleeding risk with resumption of full-dose anticoagulation outweighs the risk of thromboembolic events, postponing therapeutic anticoagulation 48–72 h after the procedure may be considered, using post-operative thromboprophylaxis until resumption of full OAC dose is deemed safe. | IIb |
| Bridging of OAC therapy is not recommended in patients with low/moderate thrombotic risk undergoing NCS. | III |
| Use of reduced-dose NOAC to attenuate the risk of post-operative bleeding is not recommended. | III |

# What is new (13)

| Recommendations | Class |
|---|---|
| ***General risk-reduction strategies — Thromboprophylaxis*** | |
| It is recommended that decisions about peri-operative thromboprophylaxis in NCS are based on individual and procedure-specific risk factors. | I |
| If thromboprophylaxis is deemed necessary, it is recommended to choose the type and duration of thromboprophylaxis (LMWH, NOAC, or fondaparinux) according to type of NCS, duration of immobilization, and patient-related factors. | I |
| In patients with a low bleeding risk, peri-operative thromboprophylaxis should be considered for a duration of up to 14 or 35 days, for total knee or hip arthroplasty, respectively. | IIa |
| NOACs in thromboprophylaxis dose may be considered as alternative treatments to LMWH after total knee and hip arthroplasty. | IIb |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (14)

| Recommendations | Class |
|---|---|
| ***General risk-reduction strategies — Patient blood management*** | |
| It is recommended to measure haemoglobin pre-operatively in patients scheduled for intermediate- to high-risk NCS. | I |
| It is recommended to treat anaemia in advance of NCS in order to reduce the need for RBC transfusion during NCS. | I |
| In patients undergoing surgery with expected blood loss of ≥500 mL, use of washed cell salvage is recommended. | I |
| It is recommended to use point-of-care diagnostics for guidance of blood component therapy, when available. | I |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (15)

| Recommendations | Class |
|---|---|
| ***General risk-reduction strategies — Patient blood management (continued)*** | |
| The use of an algorithm to diagnose and treat anaemic patients before NCS should be considered. | **IIa** |
| In patients undergoing NCS and experiencing major bleeding, administration of tranexamic acid should be considered immediately. | **IIa** |
| Use of closed-loop arterial blood sampling systems should be considered to avoid blood loss. | **IIa** |
| Application of meticulous haemostasis should be considered a routine procedure. | **IIa** |
| A feedback/monitoring programme or clinical decision support system should be considered to be assessed before blood transfusion. | **IIa** |
| Before allogenic blood transfusion, it should be considered to obtain an extensive consent about risks associated with transfusion. | **IIa** |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (16)

| Recommendations | Class |
|---|---|
| ***Specific diseases — Coronary artery disease*** | |
| Pre-operative evaluation of patients with an indication for PCI by an expert team (surgeon and cardiologist) should be considered before elective NCS. | IIa |
| ***Specific diseases — Heart failure*** | |
| In patients with HF undergoing NCS, it is recommended to regularly assess volume status and signs of organ perfusion. | I |
| A multidisciplinary team including VAD specialists is recommended for peri-operative management of patients with HF receiving mechanical circulatory support. | I |

# What is new (17)

| Recommendations | Class |
|---|---|
| ***Specific diseases — Valvular heart disease*** | |
| In patients with symptomatic severe AR or asymptomatic severe AR and LVESD >50 mm or LVESDi (LVESD/BSA) >25 mm/m$^2$ (in patients with small body size) or resting LVEF ≤50%, valve surgery is recommended prior to elective intermediate- or high-risk NCS. | I |
| In patients with moderate-to-severe rheumatic MS and symptoms or SPAP >50 mmHg, valve intervention (percutaneous mitral commissurotomy or surgery) is recommended before elective intermediate- or high-risk NCS. | I |
| In asymptomatic patients with severe AS who are scheduled for elective high-risk NCS, AVR (SAVR or TAVI) should be considered after Heart Team discussion. | IIa |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (18)

| Recommendations | Class |
|---|---|
| ***Specific diseases — Valvular heart disease (continued)*** | |
| In patients with symptomatic severe primary MR or asymptomatic severe primary MR with LV dysfunction (LVESD ≥40 mm and/or LVEF ≤60%), valve intervention (surgical or transcatheter) should be considered prior to intermediate- or high-risk NCS, if time allows. | **IIa** |
| In patients with severe secondary MR who remain symptomatic despite guideline-directed medical therapy (including CRT if indicated), valve intervention (transcatheter or surgical) should be considered before NCS, in eligible patients with an acceptable procedural risk. | **IIa** |
| In patients with severe symptomatic AS in need of time-sensitive NCS or in whom the TAVI and SAVR are not feasible, BAV may be considered before NCS as a bridge to definitive aortic valve repair. | **IIb** |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (19)

| Recommendations | Class |
|---|---|
| ***Specific diseases — Arrhythmias*** | |
| In AF patients with acute or worsening haemodynamic instability undergoing NCS, emergency electrical cardioversion is recommended. | I |
| In patients with symptomatic, monomorphic, sustained VT associated with myocardial scar, recurring despite optimal medical therapy, ablation of arrhythmia is recommended before elective NCS. | I |
| It is recommended that all patients with CIEDs which are reprogrammed before surgery, have a re-check and necessary reprogramming as soon as possible after the procedure. | I |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (20)

| Recommendations | Class |
|---|---|
| ***Specific diseases — Arrhythmias (continued)*** | |
| If indications for pacing exist according to the 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy, NCS surgery should be deferred and implantation of a permanent pacemaker should be considered. | **IIa** |
| Ablation should be considered in symptomatic patients with recurrent or persistent SVT despite treatment, prior to high-risk, non-urgent NCS. | **IIa** |
| In high-risk CIED patients (e.g with ICD or being pacing-dependant) undergoing NCS carrying a high probability of electromagnetic interference (e.g. involving unipolar electrosurgery above the umbilical area), CIED check-up and necessary reprogramming immediately before the procedure should be considered. | **IIa** |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (21)

| Recommendations | Class |
|---|---|
| ***Specific diseases — Adult congenital heart disease*** | |
| In patients with ACHD, a consultation by an ACHD specialist is recommended before intermediate- or high-risk surgery. | I |
| In patients with ACHD, it is recommended that intermediate- and high-risk elective surgery is performed in a centre with experience in the care of ACHD patients. | I |
| ***Specific diseases — Pericardial diseases*** | |
| In patients with acute pericarditis, deferring elective NCS until complete resolution of the underlying process should be considered. | IIa |
| Avoiding elective NCS procedures under general anaesthesia until colchicine or the immunosuppressive treatment course for pericardial disease is completed may be considered. | IIb |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (22)

| Recommendations | Class |
|---|---|
| ***Specific diseases — Pulmonary arterial hypertension*** | |
| Inodilator drugs (dobutamine, milrinone, levosimendan), which increase cardiac output and lower pulmonary vascular resistance, should be considered peri-operatively according to the haemodynamic status of the patient. | **IIa** |
| ***Specific diseases — Peripheral artery disease and/or abdominal aortic aneurysm*** | |
| Routine referral for cardiac work-up, coronary angiography, or CPET prior to elective surgery for PAD or AAA is not recommended. | **III** |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (23)

| Recommendations | Class |
|---|---|
| ***Specific diseases — Renal disease*** | |
| In patients with known risk factors (age >65 years, BMI >30 kg/m$^2$, diabetes, hypertension, hyperlipidaemia, CV disease or smoking) undergoing intermediate- or high-risk NCS, it is recommended to screen for pre-operative renal disease measuring serum creatinine and GFR. | I |
| In patients with renal disease requiring peri-operative contrast-enhanced radiography, a balanced hydration with i.v. isotonic fluids, the use of a minimal volume of contrast media and the use of a minimal volume of contrast media and the use of low-osmolar or iso-osmolar contrast media should be considered. | IIa |
| If a cystatin C measurement assay is available, cystatin C measurement should be considered in patients with impaired eGFR (<45–59 mL/min/1.73 m$^2$ ) to confirm kidney disease. | IIa |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (24)

| Recommendations | Class |
|---|---|
| ***Specific diseases — Obesity*** | |
| It is recommended to assess cardiorespiratory fitness to estimate peri-operative CV risk in the obese patient, with particular attention to those undergoing intermediate- and high-risk NCS. | I |
| In patients at high risk of obesity hypoventilation syndrome, additional specialist investigation before major elective NCS should be considered. | IIa |
| ***Specific diseases — Diabetes mellitus*** | |
| A pre-operative assessment for concomitant cardiac conditions is recommended in patients with diabetes with suspected or known CAD and those with autonomic neuropathy, retinopathy, or renal disease and scheduled to undergo intermediate- or high-risk NCS. | I |
| ***Peri-operative monitoring and anaesthesia*** | |
| It is recommended to avoid post-operative acute pain. | I |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (25)

| Recommendations | Class |
|---|---|
| ***Perioperative cardiovascular complications*** | |
| It is recommended to have high awareness for peri-operative CV complications combined with surveillance for PMI in patients undergoing intermediate- or high-risk NCS. | I |
| Systematic PMI work-up is recommended to identify the underlying pathophysiology and to define therapy. | I |
| It is recommended to treat post-operative STEMI, NSTE-ACS, acute HF, and tachyarrhythmias in accordance with guidelines for the non-surgical setting, after interdisciplinary discussion with the surgeon about bleeding risk. | I |
| In patients with post-operative PE of high or intermediate clinical probability, initiation of anticoagulation is recommended without delay, while diagnostic work-up is in progress, if bleeding risk is low. | I |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (26)

| Recommendations | Class |
|---|---|
| ***Perioperative cardiovascular complications (continued)*** | |
| Post-operative oral anticoagulation for PE is recommended to be administered for a period of at least 3 months. | I |
| In patients with a post-operative indication for OAC, NOACs are generally recommended over VKA. | I |
| In patients with post-operative AF after NCS, long-term OAC therapy should be considered in all patients at risk for stroke, considering the anticipated net clinical benefit of OAC therapy, as well as informed patient preferences. | IIa |
| In patients with MINS and at low risk of bleeding, treatment with dabigatran 110 mg orally twice daily may be considered from about 1 week after NCS. | IIb |
| Routine use of beta-blocker for the prevention of post-operative AF in patients undergoing NCS is not recommended. | III |

# What is new (27)

| 2014 Guidelines | Class | 2022 Guidelines | Class |
|---|---|---|---|
| ***Preoperative assessment tools — Electrocardiography and biomarkers*** | | | |
| Pre-operative ECG is recommended for patients who have risk factor(s)d and are scheduled for intermediate- or high-risk surgery. | I | In patients who have known CVD or CV risk factors (including age ≥65 years), or symptoms or signs suggestive of CVD, it is recommended to obtain a pre-operative 12-lead ECG before intermediate- and high-risk NCS. | I |
| Assessment of cardiac troponins in high-risk patients, both before and 48–72 hours after major surgery, may be considered. | IIb | In patients who have known CVD, CV risk factors (including age ≥65 years), or symptoms suggestive of CVD, it is recommended to measure hs-cTn T and hs-cTn I before intermediate- and high-risk NCS, and at 24 h, and 48 h afterwards. | I |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (28)

| 2014 Guidelines | Class | 2022 Guidelines | Class |
|---|---|---|---|
| ***Preoperative assessment tools — Electrocardiography and biomarkers (continued)*** | | | |
| NT-proBNP and BNP measurements may be considered for obtaining independent prognostic information for peri- operative and late cardiac events in high-risk patients. | **IIb** | In patients who have known CVD, CV risk factors (including age ≥65 years), or symptoms suggestive of CVD, it should be considered to measure BNP or NT-proBNP before intermediate- and high-risk NCS. | **IIa** |
| Universal pre-operative routine biomarker sampling for risk stratification and to prevent cardiac events is not recommended. | **III** | In low-risk patients undergoing low- and intermediate-risk NCS, it is not recommended to routinely obtain pre-operative ECG, hs-cTn T/I, or BNP/NT-proBNP concentrations. | **III** |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (29)

| 2014 Guidelines | Class | 2022 Guidelines | Class |
|---|---|---|---|
| ***Preoperative assessment tools — Coronary angiography*** | | | |
| Pre-operative ICA is not recommended in cardiac-stable patients undergoing low-risk surgery. | **III** | Routine pre-operative ICA is not recommended in stable CCS patients undergoing low- or intermediate-risk NCS. | **III** |
| ***General risk-reduction strategies — Pharmacological treatment*** | | | |
| Transient discontinuation of ACEIs or ARBs before non-cardiac surgery in hypertensive patients should be considered. | **IIa** | In patients without HF, withholding RAAS inhibitors on the day of NCS should be considered to prevent peri-operative hypotension. | **IIa** |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (30)

| 2014 Guidelines | Class | 2022 Guidelines | Class |
|---|---|---|---|
| ***General risk-reduction strategies — Antiplatelets*** | | | |
| Consideration should be given to performing non-urgent, non-cardiac surgery in patients who have had recent DES implantation no sooner than 12 months following the intervention. This delay may be reduced to 6 months for the new- generation DES. | **IIa** | It is recommended to delay elective NCS until 6 months after elective PCI and 12 months after an ACS, respectively. | **I** |
| It is recommended that aspirin be continued for 4 weeks after BMS implantation and for 3–12 months after DES implantation, unless the risk of life-threatening surgical bleeding on aspirin is unacceptably high. | **I** | After elective PCI, it is recommended to delay time-sensitive NCS until a minimum of 1 month of DAPT treatment has been given. | **I** |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (31)

| 2014 Guidelines | Class | 2022 Guidelines | Class |
|---|---|---|---|
| ***General risk-reduction strategies — Antiplatelets (continued)*** | | | |
| Continuation of aspirin, in patients previously thus treated, may be considered in the peri-operative period, and should be based on an individual decision that depends on the peri-operative bleeding risk, weighed against the risk of thrombotic complications. | **IIb** | In patients with a prior PCI, it is recommended to continue aspirin peri-operatively if the bleeding risk allows. | **I** |
| Discontinuation of aspirin therapy, in patients previously treated with it, should be considered in those in whom haemostasis is anticipated to be difficult to control during surgery. | **IIa** | In patients without a history of PCI, interruption of aspirin at least 3 days before NCS may be considered if the bleeding risk outweighs the ischaemic risk, to reduce the risk of bleeding. | **IIb** |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (32)

| 2014 Guidelines | Class | 2022 Guidelines | Class |
|---|---|---|---|
| ***General risk-reduction strategies — Antiplatelets (continued)*** | | | |
| In patients treated with $P2Y_{12}$ inhibitors, who need to undergo surgery, postponing surgery for at least 5 days after cessation of ticagrelor and clopidogrel—and for 7 days in the case of prasugrel—if clinically feasible, should be considered unless the patient is at high risk of an ischaemic event. | **IIa** | If interruption of $P2Y_{12}$ inhibitor is indicated, it is recommended to withhold ticagrelor for 3–5 days, clopidogrel for 5 days, and prasugrel for 7 days prior to NCS. | **I** |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (33)

| 2014 Guidelines | Class | 2022 Guidelines | Class |
|---|---|---|---|
| ***Specific diseases — Coronary artery disease*** | | | |
| If PCI is indicated before semi- urgent surgery, the use of new-generation DES, BMS or even balloon angioplasty is recommended. | I | If PCI is indicated before NCS, the use of new-generation DES is recommended over BMS and balloon angioplasty. | I |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (34)

| 2014 Guidelines | Class | 2022 Guidelines | Class |
|---|---|---|---|
| ***Specific diseases — Arrhythmias*** | | | |
| Patients with ICDs, whose devices have been pre-operatively deactivated, should be on continuous cardiac monitor throughout the period of deactivation. External defibrillation equipment should be readily available. | I | It is recommended that patients with temporarily deactivated ICDs have continuous ECG monitoring, and during the peri-operative period are accompanied by personnel skilled in early detection and treatment of arrhythmias. In high-risk patients (e.g. pacemaker dependant or ICD patients), or if access to torso will be difficult during the procedure, it is recommended to place transcutaneous pacing/defibrillation pads prior to NCS. | I |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (35)

| 2014 Guidelines | Class | 2022 Guidelines | Class |
|---|---|---|---|
| ***Specific diseases — Hypertension*** | | | |
| Large peri-operative fluctuations in blood pressure in hypertensive patients should be avoided. | IIa | In patients with chronic hypertension undergoing elective NCS it is recommended to avoid large peri-operative fluctuations in blood pressure, particularly hypotension, during the peri-operative period. | I |
| Clinicians may consider not deferring non-cardiac surgery in patients with grade 1 or 2 hypertension (systolic blood pressure <180 mm Hg; diastolic blood pressure <110 mm Hg). | IIb | It is not recommended to defer NCS in patients with stage 1 or 2 hypertension. | III |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (36)

| 2014 Guidelines | Class | 2022 Guidelines | Class |
|---|---|---|---|
| ***Specific diseases — Peripheral artery disease*** | | | |
| Patients with PAD should be clinically assessed for ischaemic heart disease and, if more than two clinical risk factors are present, they should be considered for pre-operative stress or imaging testing. | **IIa** | In patients with poor functional capacity or with significant risk factors or symptoms (such as moderate-to-severe angina pectoris, decompensated HF, valvular disease and significant arrhythmia), referral for cardiac work-up and optimization is recommended prior to elective surgery for PAD or AAA. | **I** |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (37)

| 2014 Guidelines | Class | 2022 Guidelines | Class |
|---|---|---|---|
| ***Specific diseases — Diabetes mellitus*** | | | |
| In patients at high surgical risk, clinicians should consider screening for elevated HbA1c before major surgery and improving pre-operative glucose control. | **IIa** | In patients with diabetes or disturbed glucose metabolism, a pre-operative HbA1c test is recommended, if this measurement has not been performed in the prior 3 months. In case of HbA1c ≥8.5% (≥69 mmol/mol) elective NCS should be postponed, if safe and practical. | **I** |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (38)

| 2014 Guidelines | Class | 2022 Guidelines | Class |
|---|---|---|---|
| ***Peri-operative monitoring and anaesthesia*** | | | |
| Patients with high cardiac and surgical risk should be considered for goal-directed therapy. | IIa | In order to preserve optimal CV stability, it is recommended to apply goal-directed haemodynamic therapy in patients undergoing high-risk NCS. | I |
| Avoiding arterial hypotension (mean arterial pressure <60 mmHg) for prolonged cumulative periods (>30 minutes) may be considered. | IIb | In order to minimize the risk of post-operative organ dysfunction, it is recommended to avoid intra-operative mean arterial pressure decrease of >20% from baseline values or below 60–70 mmHg for ≥10 min. | I |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# What is new (39)

| 2014 Guidelines | Class | 2022 Guidelines | Class |
|---|---|---|---|
| ***Peri-operative monitoring and anaesthesia (continued)*** | | | |
| Avoiding non-steroidal anti-inflammatory drugs (especially cyclo-oxygenase-2 inhibitors) as the first-line analgesics in patients with IHD or stroke may be considered. | **IIb** | Non-aspirin NSAIDs are not recommended as first-line analgesics in patients with established or high risk of CVD. | **III** |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Figure 1

## Total risk is an interaction of patient-related and surgery-related risk








2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Surgical risk estimate according to type of surgery or intervention

| Low surgical risk (<1%) | Intermediate surgical risk (1–5%) | High surgical risk (>5%) |
|---|---|---|
| • Breast<br>• Dental<br>• Endocrine: thyroid<br>• Eye<br>• Gynaecological: minor<br>• Orthopaedic minor (meniscectomy)<br>• Reconstructive<br>• Superficial surgery<br>• Urological minor: (transurethral resection of the prostate)<br>• VATS minor lung resection | • Carotid asymptomatic (CEA or CAS)<br>• Carotid symptomatic (CEA)<br>• Endovascular aortic aneurysm repair<br>• Head or neck surgery<br>• Intraperitoneal: splenectomy, hiatal hernia repair, cholecystectomy<br>• Intrathoracic: non-major<br>• Neurological or orthopaedic: major (hip and spine surgery)<br>• Peripheral arterial angioplasty<br>• Renal transplants<br>• Urological or gynaecological: major | • Adrenal resection<br>• Aortic and major vascular surgery<br>• Carotid symptomatic (CAS)<br>• Duodenal-pancreatic surgery<br>• Liver resection, bile duct surgery<br>• Oesophagectomy<br>• Open lower limb revascularization for acute limb ischaemia or amputation<br>• Pneumonectomy (VATS or open surgery)<br>• Pulmonary or liver transplant<br>• Repair of perforated bowel<br>• Total cystectomy |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for the selection of surgical approach and impact on risk

| Recommendations | Class | Level |
|---|---|---|
| Endovascular or video-assisted procedures should be considered for patients with high CV risk undergoing vascular or pulmonary surgery. | IIa | B |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Figure 2

## Pre-operative assessment before non-cardiac surgery








2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for all patients scheduled for non-cardiac surgery

| Recommendations | Class | Level |
|---|---|---|
| In all patients scheduled for NCS, an accurate history, and clinical examination are recommended. | I | C |
| It is recommended to perform a pre-operative risk assessment, ideally at the same time as the NCS is proposed. | I | B |
| If time allows, it is recommended to optimize guideline-recommended treatment of CVD and CV risk factors before NCS. | I | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for patients <65 years without signs, symptoms, or history of cardiovascular disease

| Recommendations | Class | Level |
|---|---|---|
| In patients with a family history of genetic cardiomyopathy, it is recommended to perform an ECG and TTE before NCS regardless of age and symptoms. | I | C |
| In patients 45–65 years of age without signs, symptoms, or history of CVD, ECG, and biomarkers should be considered before high-risk NCS. | IIa | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for pre-operative assessment in patients with previously unknown murmur, angina, dyspnoea, or peripheral oedema (1)

| Recommendations | Class | Level |
|---|---|---|
| ***Newly detected murmur*** | | |
| In patients with a newly detected murmur *and* symptoms or signs of CVD, TTE is recommended before NCS. | I | C |
| In patients with a newly detected murmur suggesting clinically significant pathology, TTE is recommended before high-risk NCS. | I | C |
| In patients with a newly detected murmur, but without other signs or symptoms of CVD, TTE should be considered before moderate and high-risk NCS. | IIa | C |
| ***Previously unknown angina*** | | |
| If a patient scheduled for elective NCS has chest pain or other symptoms suggestive of undetected CAD, further diagnostic work-up before NCS is recommended. | I | C |
| If a patient in need of acute NCS also has chest pain or other symptoms suggestive of undetected CAD, a multidisciplinary assessment approach is recommended to choose the treatment with lowest total risk for the patient. | I | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for pre-operative assessment in patients with previously unknown murmur, angina, dyspnoea, or peripheral oedema (2)

| Recommendations | Class | Level |
|---|---|---|
| ***Dyspnoea and/or peripheral oedema*** | | |
| In patients with dyspnoea and/or peripheral oedema, an ECG and an NT-proBNP/BNP test is indicated before NCS, unless there is a certain non-cardiac explanation. | I | C |
| In patients with dyspnoea and/or peripheral oedema and elevated NT-proBNP/BNP, TTE is recommended before NCS. | I | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for patient information

| Recommendations | Class | Level |
|---|---|---|
| It is recommended to give patients individualized instructions for pre-operative and post-operative changes in medication, in verbal and written formats with clear and concise directions. | I | C |
| It should be considered to set up a structured information list (e.g. a check list to help with common issues) for patients with CVD or at high risk of CV complications scheduled for NCS. | IIa | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Figure 3

## Examples of questions and concerns expressed by patients






2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Risk score calculators (1)

| | Revised Cardiac Risk Index (RCRI) (1999) | Surgical Risk Calculator (2011) | The American College of Surgery National Surgical Quality Improvement Program (ACS NSQIP) (2013) | Surgical Outcome Risk Tool (SORT) (2014) | The American University of Beirut (AUB)-HAS2 Cardiovascular Risk Index (2019) |
|---|---|---|---|---|---|
| Variables | Ischaemic heart disease<br>Cerebrovascular disease<br>History of congestive heart failure<br>Insulin therapy for diabetes<br>Serum creatinine level ≥2 mg/dL<br>High-risk surgery<br>(each assigned 1 point) | Age<br>ASA–PS grade<br>Pre-operative dependent functional status<br>Creatinine >1.5 mg/dL<br>Type of surgery | Age<br>Sex<br>Functional status<br>Emergency case<br>ASA class<br>Current steroid use<br>Ascites within 30 days<br>Systemic sepsis within 48h<br>Ventilator dependence<br>Disseminated cancer<br>Diabetes<br>Hypertension on treatment<br>Congestive HF<br>Dyspnoea<br>Current smoker<br>History of severe COPD<br>Dialysis<br>Acute renal failure<br>Body mass index<br>Surgery code | ASA–PS grade<br>Urgency of surgery<br>High-risk surgical specialty<br>Surgical severity (from minor to complex major)<br>Cancer<br>Age ≥65 years or over | History of **H**eart disease<br>Symptoms of **H**eart disease (angina or dyspnoea)<br>**A**ge ≥75 years<br>**A**naemia (haemoglobin <12 g/dL)<br>Vascular **S**urgery<br>Emergency **S**urgery<br>(2 H, 2 A and 2 S)<br>(each assigned 1 point) |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Risk score calculators (2)

| | Revised Cardiac Risk Index (RCRI) (1999) | Surgical Risk Calculator (2011) | The American College of Surgery National Surgical Quality Improvement Program (ACS NSQIP) (2013) | Surgical Outcome Risk Tool (SORT) (2014) | The American University of Beirut (AUB)-HAS2 Cardiovascular Risk Index (2019) |
|---|---|---|---|---|---|
| Score range | Score 1; risk 6.0% (4.9–7.4)<br>Score 2; risk 10.1% (8.1–10.6)<br>Score ≥3; risk 15% (11.1–20.0) | Absolute risk: 0–100% | Absolute risk: 0–100% | Absolute risk: 0–100% | Low risk (score 0–1); (0.3 and 1.6%)<br>Intermediate risk (score 2–3); (7.1 and 17%)<br>High risk (score >3); ( >17%) |
| Outcome | 30-day MI, cardiac arrest, death | Intra-operative and 30-day MI or cardiac arrest | Serious complications and any complications at 30 days | 30-day mortality | 30-day death, MI, or stroke |
| Derivation population | 1422 | 211 410 | 1 414 006 | 11 219 | 3284 |
| Validation population | Externally validated in various surgical populations | 257 385 | Externally validated in various surgical populations | 22 631 | 1 167 414 |
| Model performance (AUC) | 0.68–0.76 | 0.81–0.85 | 0.73 | 0.81-0.92 | 0.82 |
| Interactive calculator | https://www.mdcalc.com/revised-cardiac-risk-index-pre-operative-risk | http://www.surgicalriskcalculator.com/miorcardiacarrest | https://riskcalculator.facs.org | http://www.sortsurgery.com | |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for pre-operative assessment of frailty and physical capacity

| Recommendations | Class | Level |
|---|---|---|
| In patients ≥70 years old, being scheduled to undergo intermediate- or high-risk NCS, frailty screening should be considered using a validated screening tool. | IIa | B |
| Adjusting risk assessments according to self-reported ability to climb two flights of stairs should be considered in patients referred for intermediate- or high-risk NCS. | IIa | B |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Figure 4

**Recommended measurements to assess and detect the risk of post-operative cardiac complications**








2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for pre-operative risk assessment—electrocardiography and biomarkers

| Recommendations | Class | Level |
|---|---|---|
| In patients who have known CVD or CV risk factors (including age ≥65 years), or symptoms or signs suggestive of CVD, it is recommended to obtain a pre-operative 12-lead ECG before intermediate- and high-risk NCS. | I | C |
| In patients who have known CVD, CV risk factors (including age ≥65 years), or symptoms suggestive of CVD, it is recommended to measure hs-cTn T or hs-cTn I before intermediate- and high-risk NCS, and at 24 h, and 48 h afterwards. | I | B |
| In patients who have known CVD, CV risk factors (including age ≥65 years), or symptoms suggestive of CVD, it should be considered to measure BNP or NT-proBNP before intermediate- and high-risk NCS. | IIa | B |
| In low-risk patients undergoing low- and intermediate-risk NCS, it is not recommended to routinely obtain pre-operative ECG, hs-cTn T/I, or BNP/NT-proBNP concentrations. | III | B |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for transthoracic echocardiography

| Recommendations | Class | Level |
|---|---|---|
| TTE is recommended in patients with poor functional capacity and/or high NT-proBNP/BNP, or, if murmurs are detected before high-risk NCS, to undertake risk-reduction strategies. | I | B |
| TTE should be considered in patients with suspected new CVD or unexplained signs or symptoms before high-risk NCS. | IIa | B |
| TTE may be considered in patients with poor functional capacity, abnormal ECG, high NT-proBNP/BNP, or ≥1 clinical risk factor, before intermediate-risk NCS. | IIb | B |
| To avoid delaying surgery, a FOCUS exam performed by trained specialists may be considered as an alternative to TTE for pre-operative triage. | IIb | B |
| Routine pre-operative evaluation of LV function is not recommended. | III | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for stress imaging

| Recommendations | Class | Level |
|---|---|---|
| Stress imaging is recommended before high-risk elective NCS in patients with poor functional capacity and high likelihood of CAD or high clinical risk. | I | B |
| Stress imaging should be considered before high-risk NCS in asymptomatic patients with poor functional capacity, and prior PCI or CABG. | IIa | C |
| Stress imaging may be considered before intermediate-risk NCS when ischaemia is of concern in patients with clinical risk factors and poor functional capacity. | IIb | B |
| Stress imaging is not recommended routinely before NCS. | III | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for coronary angiography

| Recommendations | Class | Level |
|---|---|---|
| It is recommended to use the same indications for ICA and revascularization pre-operatively as in the non-surgical setting. | I | C |
| CCTA should be considered to rule out CAD in patients with suspected CCS or biomarker-negative NSTE-ACS in case of low-to-intermediate clinical likelihood of CAD, or in patients not suitable for non-invasive functional testing undergoing non-urgent, intermediate-, and high-risk NCS. | IIa | C |
| Pre-operative ICA may be considered in stable CCS patients undergoing elective surgical CEA. | IIb | B |
| Routine pre-operative ICA is not recommended in stable CCS patients undergoing low- or intermediate-risk NCS. | III | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for lifestyle and cardiovascular risk factors

| Recommendations | Class | Level |
|---|---|---|
| Smoking cessation more than 4 weeks before NCS is recommended to reduce post-operative complications and mortality. | I | B |
| Control of CV risk factors, including blood pressure, dyslipidaemia, and diabetes, is recommended before NCS. | I | B |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for pharmacological treatment (1)

| Recommendations | Class | Level |
|---|---|---|
| ***Initiation*** | | |
| In patients with an indication for statins, it should be considered to initiate statins peri-operatively. | IIa | C |
| Pre-operative initiation of beta-blockers in advance of high-risk NCS may be considered in patients who have ≥2 clinical risk factors, in order to reduce the incidence of peri-operative myocardial infarction. | IIb | A |
| Pre-operative initiation of beta-blocker in advance of NCS may be considered in patients who have known CAD or myocardial ischaemia. | IIb | B |
| Routine initiation of beta-blocker peri-operatively is not recommended. | III | A |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for pharmacological treatment (2)

| Recommendations | Class | Level |
|---|---|---|
| ***Continuation*** | | |
| Peri-operative continuation of beta-blockers is recommended in patients currently receiving this medication. | I | B |
| In patients already on statins, it is recommended to continue statins during the peri-operative period. | I | B |
| In patients with stable HF, peri-operative continuation of RAAS inhibitors may be considered. | IIb | C |
| ***Interruption*** | | |
| In patients without HF, withholding RAAS inhibitors on the day of NCS should be considered to prevent peri-operative hypotension. | IIa | B |
| For patients on diuretics to treat hypertension, transient discontinuation of diuretics on day of NCS should be considered. | IIa | B |
| It should be considered to interrupt SGLT-2 inhibitor therapy for at least 3 days before intermediate- and high-risk NCS. | IIa | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Pharmacokinetic and pharmacodynamic characteristics of antiplatelets

| | ASA | Clopidogrel | Prasugrel | Ticagrelor | Cangrelor | Eptifibatide | Tirofiban |
|---|---|---|---|---|---|---|---|
| **Target (type of blockade)** | COX-1 (irreversible) | $P2Y_{12}$ (irreversible) | $P2Y_{12}$ (irreversible) | $P2Y_{12}$ (reversible) | $P2Y_{12}$ (reversible) | GPIIB/IIIa (reversible) | GPIIB/IIIa (reversible) |
| **Application** | Oral | Oral | Oral | Oral | i.v. | i.v. | i.v. |
| **Time to $C_{max}$** | 0.5–1.0h | 2 h (after 600 mg LD) | 0.5 h (after 60 mg LD) | 0.5 h (after 180 mg LD) | 2 min | 5 min | 5 min |
| **Prodrug** | No | Yes | Yes | No | No | No | No |
| **Bioavailability (%)** | ~50 | ~50 | 80 | 36 | 100 | 100 | 100 |
| **Drug interactions** | NSAIDs (in particular ibuprofen + naproxen) | CYP3A4, CYP3A5, or CYP2C19 inhibitors or inducers | CYP3A4/A5 and CYP2B6 inhibitor | CYP3A4 inducers or inhibitors | None | None | None |
| **Plasma half-life** | 20 min | 0.5–1 h (active metabolite | 0.5–1 h (active metabolite) | 6–12 h | 3–6 min | 2.5–2.8 h | 1.2–2 h |
| **Duration of action after last dose** | 7–10 days | 3–10 days | 7–10 days | 3–5 days | 1–2 h | 4 h | 8 h |
| **Renal clearance of the active metabolite (%)** | NR | NR | NR | NR | 58 | ~50 | 65 |
| **Dose regimen** | o.d | o.d. | o.d. | b.i.d. | Bolus, infusion | Bolus, infusion | Bolus, infusion |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Pharmacokinetic and pharmacodynamic characteristics of oral anticoagulants

| | Warfarin | Phenprocoumon | Apixaban | Dabigatran | Edoxaban | Rivaroxaban |
|---|---|---|---|---|---|---|
| **Target (type of blockade)** | VKORC1 | VKORC1 | FXa | FIIa | FXa | FXa |
| **Application** | Oral | Oral | Oral | Oral | Oral | Oral |
| **Time to $C_{max}$** | 2–6 h | 1.52 h ± 1.52 | 3–4 h | 1.25–3 h | 1–2 h | 2–4 h |
| **Prodrug** | No | No | No | Yes | No | No |
| **Bioavailability (%)** | >95 | 100 | 50 | 6.5 | 62 | 80–100 |
| **Drug interactions** | CYP2C9, CYP2C19, CYP2C8, CYP2C18, CYP1A2, CYP3A4, vitamin K | CYP2C9, CYP2C8, vitamin K | CYP3A4 inhibitors or inductors, P-glycoprotein inhibitors or inductors | P-glycoprotein inhibitors or inductors | P-glycoprotein inhibitors | CYP3A4 inhibitors or inductors, P-glycoprotein inhibitors or inductors |
| **Plasma half-life** | 36–48 h | ~100 h | 12 h | 12–14 h | 6–11 h | 7–11 h (11–13 h in the elderly) |
| **Duration of action after last dose** | ~5 days | ~7 days | 24 h | 24 h | 24 h | 24 h |
| **Renal clearance of the active metabolite (%)** | Non-renal | Non-renal | 27 | 85 | 37–50 | 33 |
| **Dose regimen** | Adjusted according to INR | Adjusted according to INR | b.i.d. | b.i.d. | o.d. | o.d./b.i.d. |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Bleeding risk according to type of non-cardiac surgery

| Surgery with minor bleeding risk | Surgery with low bleeding risk (infrequent or with low clinical impact) | Surgery with high bleeding risk (frequent or with significant clinical impact) |
|---|---|---|
| • Cataract or glaucoma procedure<br>• Dental procedures: extractions (1–3 teeth), periodontal surgery, implant positioning, endodontic (root canal) procedures, subgingival scaling/cleaning<br>• Endoscopy without biopsy or resection<br>• Superficial surgery (e.g. abscess incision, small skin excisions/biopsy) | • Abdominal surgery: cholecystectomy, hernia repair, colon resection<br>• Breast surgery<br>• Complex dental procedures (multiple tooth extractions)<br>• Endoscopy with simple biopsy<br>• Gastroscopy or colonoscopy with simple biopsy<br>• Large-bore needles procedures, e.g. bone marrow or lymph node biopsy<br>• Non-cataract ophthalmic surgery<br>• Small orthopaedic surgery (foot, hand arthroscopy) | • Abdominal surgery with liver biopsy, extracorporeal shockwave lithotripsy<br>• Extensive cancer surgery (e.g. pancreas, liver)<br>• Neuraxial (spinal or epidural) anaesthesia<br>• Neurosurgery (intracranial, spinal)<br>• Major orthopaedic surgery<br>• Procedures with vascular organ biopsy (kidney or prostate)<br>• Reconstructive plastic surgery<br>• Specific interventions (colon polypectomy, lumbar puncture, endovascular aneurysm repair)<br>• Thoracic surgery, lung resection surgery<br>• Urological surgery (prostatectomy, bladder tumour resection)<br>• Vascular surgery (e.g. AAA repair, vascular bypass) |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Figure 5

## Recommendations for management of antiplatelet therapy in patients undergoing non-cardiac surgery








2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Figure 6

## $P2Y_{12}$ inhibitor interruption after percutaneous coronary intervention before elective non-cardiac surgery








2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Figure 7

## Bridging with intravenous antiplatelet agents








2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for the use of antiplatelet therapy in patients undergoing non-cardiac surgery (1)

| Recommendations | Class | Level |
|---|---|---|
| It is recommended to delay elective NCS until 6 months after elective PCI and 12 months after an ACS, respectively. | I | A |
| After elective PCI, it is recommended to delay time-sensitive NCS until a minimum of 1 month of DAPT treatment has been given. | I | B |
| In patients with a recent PCI scheduled for NCS, it is recommended that management of antiplatelet therapy is discussed between the surgeon, the anaesthesiologist, and the cardiologist. | I | C |
| In high-risk patients with a recent PCI (e.g. STEMI patients or high-risk NSTE-ACS patients), a DAPT duration of at least 3 months should be considered before time-sensitive NCS. | IIa | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for the use of antiplatelet therapy in patients undergoing non-cardiac surgery (2)

| Recommendations | Class | Level |
|---|---|---|
| ***Continuation of medication*** | | |
| In patients with a prior PCI, it is recommended to continue aspirin peri-operatively if the bleeding risk allows. | I | B |
| ***Recommended time interval for drug interruption before NCS*** | | |
| If interruption of $P2Y_{12}$ inhibitor is indicated, it is recommended to withhold ticagrelor for 3–5 days, clopidogrel for 5 days, and prasugrel for 7 days prior to NCS. | I | B |
| For patients undergoing high bleeding risk surgery (e.g. intracranial, spinal neurosurgery, or vitroretinal eye surgery), it is recommended to interrupt aspirin for at least 7 days pre-operatively. | I | C |
| In patients without a history of PCI, interruption of aspirin at least 3 days before NCS may be considered if the bleeding risk outweighs the ischaemic risk, to reduce the risk of bleeding. | IIb | B |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for the use of antiplatelet therapy in patients undergoing non-cardiac surgery (3)

| Recommendations | Class | Level |
|---|---|---|
| ***Resumption of medication*** | | |
| If antiplatelet therapy has been interrupted before a surgical procedure, it is recommended to restart therapy as soon as possible (within 48 h) post-surgery, according to interdisciplinary risk assessment. | I | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Figure 8

## Recommendations for management of oral anticoagulation therapy in patients undergoing non-cardiac surgery








2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Figure 9

## Peri-operative management of non-vitamin K antagonist oral anticoagulant according to the periprocedural risk of bleeding








2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Figure 10

## Timing of last NOAC dose before elective NCS according to renal function








2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Figure 11

## Suggested strategy for potential reversal of non-vitamin K oral anticoagulants anticoagulant effect








2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for interruption and resumption of anticoagulants in patients undergoing non-cardiac surgery (1)

| Recommendations | Class | Level |
|---|---|---|
| ***Interruption of anticoagulation*** | | |
| When an urgent surgical intervention is required, it is recommended that NOAC therapy is immediately interrupted. | I | C |
| Idarucizumab should be considered in patients on dabigatran and requiring urgent surgical intervention with intermediate to high bleeding risk. | IIa | B |
| In non-minor bleeding risk procedures in patients using a NOAC, it is recommended to use an interruption regimen based on the NOAC compound, renal function, and bleeding risk. | I | B |
| For interventions with a very high risk of bleeding, such as spinal or epidural anaesthesia, interruption of NOACs for up to five half-lives and re-initiation after 24 h should be considered. | IIa | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for interruption and resumption of anticoagulants in patients undergoing non-cardiac surgery (2)

| Recommendations | Class | Level |
|---|---|---|
| ***Interruption of anticoagulation (continued)*** | | |
| When specific reversal agents are not available, PCC or activated PCC should be considered for reversing NOAC effects. | IIa | C |
| If an urgent surgical intervention is required, specific coagulation tests and assessment of NOAC plasma levels should be considered to interpret routine coagulation tests and waning of anticoagulant effect. | IIa | C |
| ***Continuation of medication*** | | |
| In minor bleeding risk surgery and other procedures where bleeding can be easily controlled, it is recommended to perform surgery without interruption of OAC therapy. | I | B |
| LMWH is recommended, as an alternative to UFH, for bridging in patients with MHVs and high surgical risk. | I | B |
| In patients using NOACs, it is recommended that minor bleeding risk procedures are performed at trough levels (typically 12–24 h after last intake). | I | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for interruption and resumption of anticoagulants in patients undergoing non-cardiac surgery (3)

| Recommendations | Class | Level |
|---|---|---|
| ***Continuation of medication (continued)*** | | |
| For patients with mechanical prosthetic heart valves undergoing NCS, bridging with UFH or LMWH should be considered if OAC interruption is needed and patients have: (i) mechanical AVR and any thromboembolic risk factor; (ii) old-generation mechanical AVR; or (iii) mechanical mitral or tricuspidal valve replacement. | IIa | C |
| Bridging of OAC therapy is not recommended in patients with low/moderate thrombotic risk undergoing NCS. | III | B |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for interruption and resumption of anticoagulants in patients undergoing non-cardiac surgery (4)

| Recommendations | Class | Level |
|---|---|---|
| ***Start/resumption of medication*** | | |
| If bleeding risk with resumption of full-dose anticoagulation outweighs the risk of thromboembolic events, postponing therapeutic anticoagulation 48–72 h after the procedure may be considered, using post-operative thromboprophylaxis until resumption of full OAC dose is deemed safe. | IIb | C |
| Use of reduced-dose NOAC to attenuate the risk of post-operative bleeding is not recommended. | III | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations on thromboprophylaxis

| Recommendations | Class | Level |
|---|---|---|
| It is recommended that decisions about peri-operative thromboprophylaxis in NCS are based on individual and procedure-specific risk factors. | I | A |
| If thromboprophylaxis is deemed necessary, it is recommended to choose the type and duration of thromboprophylaxis (LMWH, NOAC, or fondaparinux) according to type of NCS, duration of immobilization, and patient-related factors. | I | A |
| In patients with a low bleeding risk, peri-operative thromboprophylaxis should be considered for a duration of up to 14 or 35 days, for total knee or hip arthroplasty, respectively. | IIa | A |
| NOACs in thromboprophylaxis dose may be considered as alternative treatments to LMWH after total knee and hip arthroplasty. | IIb | A |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Laboratory parameters for the diagnosis of absolute iron-deficiency anaemia

| Parameter | Normal | Iron deficiency |
|---|---|---|
| Mean corpuscular haemoglobin (g/dL) | 28–33 | <27 |
| Mean cellular volume (fL) | 80–96 | <80 |
| Transferrin saturation (%) | 16–45 | <20 |
| Ferritin (ng/mL) | 18–360 | <30 |
| Reticulocytes haemoglobin (ng/mL) | 18–360 | <30 |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for intra- and post-operative complications associated with anaemia

| Recommendations | Class | Level |
|---|---|---|
| It is recommended to measure haemoglobin pre-operatively in patients scheduled for intermediate- to high-risk NCS. | I | B |
| It is recommended to treat anaemia in advance of NCS in order to reduce the need for RBC transfusion during NCS. | I | A |
| The use of an algorithm to diagnose and treat anaemic patients before NCS should be considered. | IIa | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for intra- and post-operative complications associated with blood loss

| Recommendations | Class | Level |
|---|---|---|
| In patients undergoing surgery with expected blood loss of ≥500 mL, use of washed cell salvage is recommended. | I | A |
| It is recommended to use point-of-care diagnostics for guidance of blood component therapy, when available. | I | A |
| In patients undergoing NCS and experiencing major bleeding, administration of tranexamic acid should be considered immediately. | IIa | A |
| Use of closed-loop arterial blood sampling systems should be considered to avoid blood loss. | IIa | B |
| Application of meticulous haemostasis should be considered a routine procedure. | IIa | B |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for intra- and post-operative complications associated with allogeneic blood transfusion

| Recommendations | Class | Level |
|---|---|---|
| A feedback/monitoring programme or clinical decision support system should be considered to be assessed before blood transfusion. | IIa | B |
| Before allogenic blood transfusion, it should be considered to obtain an extensive consent about risks associated with transfusion. | IIa | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Figure 12

## Management of patients with acute or chronic coronary syndrome scheduled for non-cardiac surgery








2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations on the timing of non-cardiac surgery and revascularization in patients with known coronary artery disease (1)

| Recommendations | Class | Level |
|---|---|---|
| ***Patients with CCS*** | | |
| If PCI is indicated before NCS, the use of new-generation DES is recommended over BMS and balloon angioplasty. | I | A |
| Pre-operative evaluation of patients with an indication for PCI by an expert team (surgeon and cardiologist) should be considered before elective NCS. | IIa | C |
| Myocardial revascularization before high-risk elective NCS may be considered, depending on the amount of ischaemic myocardium, refractory symptoms, and findings at coronary angiography (as in the case of left main disease). | IIb | B |
| Routine myocardial revascularization before low- and intermediate-risk NCS in patients with CCS is not recommended. | III | B |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations on the timing of non-cardiac surgery and revascularization in patients with known coronary artery disease (2)

| Recommendations | Class | Level |
|---|---|---|
| ***Patients with ACS*** | | |
| If NCS can safely be postponed (e.g. at least 3 months), it is recommended that patients with ACS being scheduled for NCS undergo diagnostic and therapeutic interventions as recommended for ACS patients in general. | I | A |
| In the unlikely combination of a life-threatening clinical condition requiring urgent NCS, and NSTE-ACS with an indication for revascularization, the priorities for surgery on a case-by-case basis should be considered by the expert team. | IIa | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Peri-operative approach to patients with ventricular assist devices undergoing non-cardiac surgery

| Pre-operative | Intra-operative | Post-operative |
|---|---|---|
| • Multidisciplinary team identified (primary surgical and anaesthesia teams, cardiac surgery, HF cardiologist, VAD personnel)<br>• Pre-operative medical optimization when possible or necessary<br>• Physical examination focused on the sequelae of HF<br>• Baseline ECG, echocardiogram, and laboratory values<br>• Manage pacemaker/ICD settings when indicated<br>• CT examination to evaluate possible driveline interference with the operative field<br>• Hold, bridge, or reverse anticoagulation when indicated, after VAD team consultation | • Standard American Society of Anesthesiologists monitors<br>• Cerebral tissue oxygenation, processed electroencephalogram, arterial line with ultrasound guidance, central venous catheter if fluid shifts are expected, PA catheter only if severe pulmonary hypertension, TEE available<br>• Monitor VAD control console<br>• External defibrillator pads in place<br>• Optimize pre-load, support RV function, avoid increase in afterload<br>• Gradual peritoneal insufflations and position changes | • Standard post-anaesthesia care unit unless ICU is otherwise indicated<br>• Extubation criteria are unchanged<br>• Avoid hypoventilation, optimize oxygenation<br>• Resume heparin infusion when post-op bleeding risk is acceptable |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for management of heart failure in patients undergoing non-cardiac surgery

| Recommendations | Class | Level |
|---|---|---|
| In patients with suspected or known HF scheduled for high-risk NCS, it is recommended to evaluate LV function with echocardiography and measurement of NT-proBNP/BNP levels, unless this has recently been performed. | I | B |
| It is recommended that patients with HF undergoing NCS receive optimal medical treatment according to current ESC Guidelines. | I | A |
| In patients with HF undergoing NCS, it is recommended to regularly assess volume status and signs of organ perfusion. | I | C |
| A multidisciplinary team including VAD specialists is recommended for peri-operative management of patients with HF receiving mechanical circulatory support. | I | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Figure 13

## Management of patients with severe aortic valve stenosis scheduled for non-cardiac surgery








2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Figure 14

## Management of patients with secondary mitral valve regurgitation scheduled for non-cardiac surgery








2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for management of valvular heart disease in patients undergoing non-cardiac surgery (1)

| Recommendations | Class | Level |
|---|---|---|
| Clinical and echocardiographic evaluation (if not recently performed) is recommended in all patients with known or suspected VHD who are scheduled for elective intermediate- or high-risk NCS. | I | C |
| ***Aortic valve stenosis*** | | |
| AVR (SAVR or TAVI) is recommended in symptomatic patients with severe AS who are scheduled for elective intermediate- or high-risk NCS. | I | C |
| In asymptomatic patients with severe AS who are scheduled for elective high-risk NCS, AVR (SAVR or TAVI) should be considered after Heart Team discussion. | IIa | C |
| In patients with severe symptomatic AS in need of time-sensitive NCS or in whom the TAVI and SAVR are not feasible, BAV may be considered before NCS as a bridge to definitive aortic valve repair. | IIb | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for management of valvular heart disease in patients undergoing non-cardiac surgery (2)

| Recommendations | Class | Level |
|---|---|---|
| ***Aortic valve regurgitation*** | | |
| In patients with symptomatic severe AR or asymptomatic severe AR and LVESD >50 mm or LVESDi (LVESD/BSA) >25 mm/m$^2$ (in patients with small body size) or resting LVEF ≤50%, valve surgery is recommended prior to elective intermediate- or high-risk NCS. | I | C |
| ***Mitral valve stenosis*** | | |
| In patients with moderate-to-severe rheumatic MS and symptoms or SPAP >50 mmHg, valve intervention (PMC or surgery) is recommended before elective intermediate- or high-risk NCS. | I | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for management of valvular heart disease in patients undergoing non-cardiac surgery (3)

| Recommendations | Class | Level |
|---|---|---|
| ***Mitral valve regurgitation*** | | |
| In patients with symptomatic severe primary MR or asymptomatic severe primary MR with LV dysfunction (LVESD ≥40 mm and/or LVEF ≤60%), valve intervention (surgical or transcatheter) should be considered prior to intermediate- or high-risk NCS, if time allows. | IIa | C |
| In patients with severe secondary MR who remain symptomatic despite guideline-directed medical therapy (including CRT if indicated), valve intervention (transcatheter or surgical) should be considered before NCS, in eligible patients with an acceptable procedural risk. | IIa | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for management of known or newly diagnosed arrhythmias (1)

| Recommendations | Class | Level |
|---|---|---|
| ***Supraventricular arrhythmias*** | | |
| In patients with SVT controlled by medication, it is recommended that AADs are continued during the peri-operative period. | I | C |
| Ablation should be considered in symptomatic patients with recurrent or persistent SVT despite treatment, prior to high-risk, non-urgent NCS. | IIa | B |
| ***AF with haemodynamic instability in patients undergoing NCS*** | | |
| In AF patients with acute or worsening haemodynamic instability undergoing NCS, emergency electrical cardioversion is recommended. | I | B |
| In AF patients with haemodynamic instability, amiodarone may be considered for acute control of heart rate. | IIb | B |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for management of known or newly diagnosed arrhythmias (2)

| Recommendations | Class | Level |
|---|---|---|
| ***Ventricular arrhythmias*** | | |
| In patients with symptomatic, monomorphic, sustained VT associated with myocardial scar, recurring despite optimal medical therapy, ablation of arrhythmia is recommended before elective NCS. | I | B |
| It is not recommended to initiate treatment of asymptomatic PVCs during NCS. | III | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Peri-operative management of patients with arrhythmias

| Type of arrhythmia | SVT | Idiopathic VT in structurally/functionally normal heart | VT in structural heart disease |
|---|---|---|---|
| **Diagnostics** | • ECG ± TTE | • ECG ± TTE | • ECG + TTE + biomarkers<br>• ± Coronary angiography<br>• ± Cardiac CT/MRI |
| **Acute management** | • Vagal manoeuvres<br>• I.v. adenosine, beta-blocker, CCB<br>• Electrical cardioversion if unstable | • Vagal manoeuvres<br>• I.v. beta-blockers/ verapamil<br>• Electrical cardioversion if unstable | • Treatment of underlying heart disease<br>• I.v. betablocker (uptitration), amiodarone<br>• Electrical cardioversion if unstable |
| **Prevention of recurrence** | • Per oral beta-blocker, CCB<br>• Catheter ablation if recurrent despite OMT (only before high-risk NCS) | • No treatment or<br>• Per oral beta-blocker, CCB, class I AAD<br>• Catheter ablation in case of recurrence despite AADs or drug-intolerance before high-risk NCS | • Per oral beta-blocker, amiodarone<br>• Catheter ablation if recurrent despite OMT |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for management of bradyarrhythmia and patients carrying cardiac implantable devices (1)

| Recommendations | Class | Level |
|---|---|---|
| If indications for pacing exist according to the 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy, NCS surgery should be deferred and implantation of a permanent pacemaker should be considered. | IIa | C |
| It is recommended that patients with temporarily deactivated ICDs have continuous ECG monitoring, and during the peri-operative period are accompanied by personnel skilled in early detection and treatment of arrhythmias. In high-risk patients (e.g. pacemaker dependant or ICD patients), or if access to torso will be difficult during the procedure, it is recommended to place transcutaneous pacing/defibrillation pads prior to NCS. | I | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for management of bradyarrhythmia and patients carrying cardiac implantable devices (2)

| Recommendations | Class | Level |
|---|---|---|
| ***Ventricular arrhythmias*** | | |
| It is recommended that all patients with CIEDs which are reprogrammed before surgery, have a re-check and necessary reprogramming as soon as possible after the procedure. | I | C |
| In high-risk CIED patients (e.g with ICD or being pacing-dependant) undergoing NCS carrying a high probability of electromagnetic interference (e.g. involving unipolar electrosurgery above the umbilical area), CIED check-up and necessary reprogramming immediately before the procedure should be considered. | IIa | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Figure 15

**Optimal location of return electrode during unipolar electrosurgery in patients with cardiac implantable electronic devices, depending on the surgery site**








2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Risk stratification for non-cardiac surgery in adults with congenital heart disease

| | |
|---|---|
| **Minor risk** | Patients with small, uncorrected defects, and no need for medication or any other treatment<br>Patients with successfully corrected CHD with no symptoms, no relevant residua, and no need for medication |
| **Intermediate risk** | Patients with corrected or uncorrected conditions with residual haemodynamic abnormality, with or without medication |
| **Severe risk** | Patients with uncorrected cyanotic heart disease, pulmonary hypertension, other complex CHD, ventricular dysfunction requiring medication, and patients listed for heart transplantation |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for management of patients with adult congenital heart disease undergoing non-cardiac surgery

| Recommendations | Class | Level |
|---|---|---|
| In patients with ACHD, a consultation by an ACHD specialist is recommended before intermediate- or high-risk surgery. | I | C |
| In patients with ACHD, it is recommended that intermediate- and high-risk elective surgery is performed in a centre with experience in the care of ACHD patients. | I | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for pericardial diseases

| Recommendations | Class | Level |
|---|---|---|
| In patients with acute pericarditis, deferring elective NCS until complete resolution of the underlying process should be considered. | IIa | C |
| Avoiding elective NCS procedures under general anaesthesia until colchicine or the immunosuppressive treatment course for pericardial disease is completed may be considered. | IIb | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Patient-related and surgery-related factors to be considered when assessing peri-operative risk in patients with pulmonary arterial hypertension

| Patient-related peri-operative risk factors in patients with PAH | Surgery-related peri-operative risk factors in patients with PAH |
|---|---|
| • Functional class >II<br>• Reduced six-minute walk distance<br>• Coronary heart disease<br>• Previous pulmonary embolism<br>• Chronic renal insufficiency<br>• Severe right ventricular dysfunction | • Emergency surgery<br>• Duration of anaesthesia >3 h<br>• Intra-operative requirement for vasopressors |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for patients with pulmonary arterial hypertension undergoing non-cardiac surgery

| Recommendations | Class | Level |
|---|---|---|
| It is recommended to continue chronic therapy for PAH in the peri-operative phase of NCS. | I | C |
| It is recommended that haemodynamic monitoring of patients with severe PAH continues for at least 24 h in the post-operative period. | I | C |
| In the case of progression of right HF in the post-operative period in patients with PAH, it is recommended that the diuretic dose be optimized and, if necessary, i.v. prostacyclin analogues be initiated under the guidance of a physician experienced in the management of PAH. | I | C |
| Inodilator drugs (dobutamine, milrinone, levosimendan), which increase cardiac output and lower pulmonary vascular resistance, should be considered peri-operatively according to the haemodynamic status of the patient. | IIa | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for pre-operative management of hypertension

| Recommendations | Class | Level |
|---|---|---|
| In patients with chronic hypertension undergoing elective NCS it is recommended to avoid large peri-operative fluctuations in blood pressure, particularly hypotension, during the peri-operative period. | I | A |
| It is recommended to perform pre-operative screening for hypertension-mediated organ damage and CV risk factors in newly diagnosed hypertensive patients who are scheduled for elective high-risk NCS. | I | C |
| It is not recommended to defer NCS in patients with stage 1 or 2 hypertension. | III | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for management of patients with peripheral artery disease and/or abdominal aortic aneurysm undergoing non-cardiac surgery

| Recommendations | Class | Level |
|---|---|---|
| In patients with poor functional capacity or with significant risk factors or symptoms (such as moderate-to-severe angina pectoris, decompensated HF, valvular disease and significant arrhythmia), referral for cardiac work-up and optimization is recommended prior to elective surgery for PAD or AAA. | I | C |
| Routine referral for cardiac work-up, coronary angiography, or CPET prior to elective surgery for PAD or AAA is not recommended. | III | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for management of patients with suspected or established carotid artery disease undergoing non-cardiac surgery

| Recommendations | Class | Level |
|---|---|---|
| Pre-operative carotid artery and cerebral imaging is recommended in patients with a history of TIA or stroke in the previous 6 months who have not undergone ipsilateral revascularization. | I | C |
| For patients with carotid artery disease undergoing NCS, the same indications for carotid revascularization should be considered as for other patients with carotid stenosis. | IIa | C |
| Pre-operative carotid artery imaging is not recommended routinely in patients undergoing NCS. | III | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for management of patients with renal disease undergoing non-cardiac surgery

| Recommendations | Class | Level |
|---|---|---|
| In patients with renal disease requiring peri-operative contrast-enhanced radiography, a balanced hydration with i.v. isotonic fluids, the use of a minimal volume of contrast media and the use of a minimal volume of contrast media and the use of low-osmolar or iso-osmolar contrast media should be considered. | IIa | B |
| In patients with known risk factors (age >65 years, BMI >30 kg/m$^2$, diabetes, hypertension, hyperlipidaemia, CV disease or smoking) undergoing intermediate- or high-risk NCS, it is recommended to screen for pre-operative renal disease measuring serum creatinine and GFR. | I | C |
| If a cystatin C measurement assay is available, cystatin C measurement should be considered in patients with impaired eGFR (<45–59 mL/min/1.73 m$^2$) to confirm kidney disease. | IIa | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for management of patients with obesity undergoing non-cardiac surgery

| Recommendations | Class | Level |
|---|---|---|
| It is recommended to assess cardiorespiratory fitness to estimate peri-operative CV risk in the obese patient, with particular attention to those undergoing intermediate- and high-risk NCS. | I | B |
| In patients at high risk of obesity hypoventilation syndrome, additional specialist investigation before major elective NCS should be considered. | IIa | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for management of patients with diabetes mellitus undergoing non-cardiac surgery

| Recommendations | Class | Level |
|---|---|---|
| In patients with diabetes or disturbed glucose metabolism, a pre-operative HbA1c test is recommended, if this measurement has been not performed in the prior 3 months. In case of HbA1c ≥8.5% (≥69 mmol/mol), elective NCS should be postponed, if safe and practical. | I | B |
| A pre-operative assessment for concomitant cardiac conditions is recommended in patients with diabetes with suspected or known CAD and those with autonomic neuropathy, retinopathy, or renal disease and scheduled to undergo intermediate- or high-risk NCS. | I | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Factors that could influence peri-operative risk during cancer surgery and preventive strategies

| | Factors that could influence peri-operative risk during cancer surgery | Preventive strategies |
|---|---|---|
| **Patient-related factors** | • Lifestyle risk factors—smoking, obesity, sedentary lifestyle<br>• Poorly controlled CV risk factors—hypertension, diabetes<br>• Pre-existing CVD, including cancer therapy-related cardiovascular toxicity<br>• Cardiac medications increasing peri-operative bleeding risk (e.g. antiplatelets and anticoagulants)<br>• Historical primary malignancy<br>• Current cancer type, stage, and location<br>• Arrhythmias (due to myocardial cancer invasion, induced QT-prolongation, AF, or imbalance of autonomic nervous system) | • Optimal management of CV risk factors and CVD<br>• Optimize preventive strategies with respect to VTE and arterial thromboembolic events<br>• ECG monitoring for arrhythmias<br>• Correction of all proarrhythmic conditions |
| **Neoadjuvant cancer therapy** | • Previous cardiotoxic cancer treatments (especially anthracycline chemotherapy and/or trastuzumab; immune checkpoint inhibitors, VEGFi, fluoropyrimidine and thoracic radiotherapy)<br>• Cancer treatments increasing peri-operative bleeding risk (e.g. antiangiogenics, BTKi)<br>• Cancer treatments increasing risk of arrhythmias | • Ensure optimal CV monitoring of neoadjuvant therapy<br>• Optimize preventive strategies with respect to VTE and arterial thromboembolic events |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Figure 16

## Pathophysiological approach to address intra-operative hypotension








2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for peri-operative monitoring and anaesthesia

| Recommendations | Class | Level |
|---|---|---|
| In order to preserve optimal CV stability, it is recommended to apply goal-directed haemodynamic therapy in patients undergoing high-risk NCS. | I | A |
| It is recommended to avoid post-operative acute pain. | I | B |
| In order to minimize the risk of post-operative organ dysfunction, it is recommended to avoid intra-operative mean arterial pressure decrease of >20% from baseline values or below 60–70 mmHg for ≥10 min. | I | B |
| Non-aspirin NSAIDs are not recommended as first-line analgesics in patients with established or high risk of CVD. | III | B |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Figure 17

## Factors associated with peri-operative cardiovascular complications








2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Figure 18

## Differential diagnosis of elevated post-operative cardiac troponin concentrations








2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Figure 19

## Systematic work-up (aetiology) and therapy of peri-operative myocardial infarction/injury








2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Figure 20

## Prevention and management of post-operative atrial fibrillation








2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for peri-operative cardiovascular complications (1)

| Recommendations | Class | Level |
|---|---|---|
| It is recommended to have high awareness for peri-operative CV complications combined with surveillance for PMI in patients undergoing intermediate- or high-risk NCS. | I | B |
| Systematic PMI work-up is recommended to identify the underlying pathophysiology and to define therapy. | I | B |
| It is recommended to treat post-operative STEMI, NSTE-ACS, acute HF, and tachyarrhythmias in accordance with guidelines for the non-surgical setting, after interdisciplinary discussion with the surgeon about bleeding risk. | I | C |
| In patients with post-operative PE of high or intermediate clinical probability, initiation of anticoagulation is recommended without delay, while diagnostic work-up is in progress, if bleeding risk is low. | I | C |
| Post-operative oral anticoagulation for PE is recommended to be administered for a period of at least 3 months. | I | C |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Recommendations for peri-operative cardiovascular complications (2)

| Recommendations | Class | Level |
|---|---|---|
| In patients with a post-operative indication for OAC, NOACs are generally recommended over VKA. | I | A |
| In patients with post-operative AF after NCS, long-term OAC therapy should be considered in all patients at risk for stroke, considering the anticipated net clinical benefit of OAC therapy, as well as informed patient preferences. | IIa | B |
| In patients with MINS and at low risk of bleeding, treatment with dabigatran 110 mg orally twice daily may be considered from about 1 week after NCS. | IIb | B |
| Routine use of beta-blocker for the prevention of post-operative AF in patients undergoing NCS is not recommended. | III | B |





2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

# Figure 21 Central illustration

**The complex interplay between the intrinsic risk of surgery and the patient risk of peri-operative cardiovascular complications**








2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
(European Heart Journal; 2022 – doi:10.1093/eurheartj/ehac270)

## ESC Pocket Guidelines




## ESC Pocket Guidelines App




## Official ESC Guidelines slide set




## ESC Essential messages